Răzvan Cristescu
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)China Railway Construction Corporation (China)(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy(2018)2,283 cited
- → Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes(2015)2,209 cited
- → Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer(2018)1,688 cited
- → T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028(2018)980 cited
- → An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies(2016)413 cited
- → On network correlated data gathering(2005)335 cited